Author: Sinanovic, Edina
Similar Items: Does the inclusion of the cost and burden of adverse drug reactions associated with drug-resistant TB treatment affect the incremental cost-effectiveness of new treatment regimens? A case study from the introduction of bedaquiline in South Africa National TB Programme
- Nonlinear mixed-effects modelling of drug-drug interactions between antiretroviral therapy and tuberculosis treatment
- Strategies for optimising TB-HIV co-treatment in children and adolescents with drug-susceptible tuberculosis on rifampicin-based standard regimens
- Performance of host blood transcriptomic signatures for TB diagnosis and monitoring TB treatment
- Investigating permeation of anti-mycobacterial agents in Mycobacterium tuberculosis and M. tuberculosis-infected macrophages in vitro as a model for early stage tuberculosis drug discovery
- Population pharmacokinetic modelling to optimise treatment for children with Rifampicin-resistant TB and HIV
- Outcomes of patients undergoing lung resection for drug-resistant TB and the prognostic significance of pre-operative positron emission tomography/computed tomography (PET/CT) in predicting treatment failure